Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma.

Trial Profile

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2009

At a glance

  • Drugs Elotuzumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 30 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov record (NCT00425347).
    • 30 Sep 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov record (NCT00425347).
    • 29 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (NCT00425347).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top